Form 4: Journey Medical COO Granted Significant Equity Awards Under Company Stock Plan

Journey Medical Corp's Chief Operating Officer, Ramsey Alloush, was granted 46,863 restricted stock units and 62,795 stock options on June 17, 2025, as part of the company's 2015 Stock Plan.

Summary

• Ramsey Alloush, Chief Operating Officer of Journey Medical Corp (DERM), received new equity awards on June 17, 2025.
• The awards include 46,863 restricted stock units (RSUs) granted at a price of $0.
• These RSUs will vest in three equal annual installments: 15,621 shares on January 1, 2026, 15,621 shares on January 1, 2027, and 15,621 shares on January 1, 2028.
• Following this transaction, Mr. Alloush beneficially owns 551,680 non-derivative securities, which include other restricted stock units vesting over various time periods.
• Additionally, Mr. Alloush was granted 62,795 stock options with an exercise price of $6.31 per share.
• These stock options will also vest in three annual installments: 20,932 shares on January 1, 2026, 20,932 shares on January 1, 2027, and 20,931 shares on January 1, 2028.
• The stock options have an expiration date of June 17, 2035.
• All grants were made pursuant to the Issuer's 2015 Stock Plan, as amended.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of executive compensation, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. No negative information is present.

Positives

• The grant of restricted stock units and stock options serves as a form of long-term incentive and retention for a key executive, aligning their interests with shareholder value.
• The vesting schedule over three years encourages continued commitment and performance from the Chief Operating Officer.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend through January 1, 2028, indicating a continued long-term incentive structure for the Chief Operating Officer.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation, common across all industries, reflecting a company's use of equity awards to incentivize and retain key personnel. It does not provide broader industry trends.

Management Changes

Corporate Governance

Related Party Transactions

• The grant of 46,863 restricted stock units and 62,795 stock options to Ramsey Alloush, the Chief Operating Officer, constitutes a related party transaction between the company and a key executive.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon vesting and exercise, but also benefit from incentivized executive performance.
• Employees (specifically COO): Direct positive impact through increased equity ownership and long-term compensation.

Next Steps

• Vesting of 15,621 restricted stock units and 20,932 stock options on January 1, 2026.
• Vesting of 15,621 restricted stock units and 20,932 stock options on January 1, 2027.
• Vesting of 15,621 restricted stock units and 20,931 stock options on January 1, 2028.

Key Dates

Keywords

SEC Form 4, insider transaction, executive compensation, restricted stock units, stock options, Journey Medical Corp, DERM, Ramsey Alloush, Chief Operating Officer, equity awards